Sanofi India
NSE: SANOFI · ISIN INE058A01010 · Healthcare
₹3,325.10+23.20 (+0.70%)
Monday 9 November, 12:05 IST. Delayed. Source: Yahoo Finance.
Price chart
₹3,325.10 +23.20 (+0.70%) today
The day
- Previous close
- ₹3,301.90
- Open
- ₹3,289.90
- Day high
- ₹3,330.00
- Day low
- ₹3,280.00
Listed on NSE since 19 May 2003.
Key numbers
- Market value
- ₹7,604.48 Cr
- P/E (trailing)
- 20.86
- EPS (trailing)
- ₹158.27
- Price to book
- 9.21
- Dividend yield
- 3.75%
- Debt to equity
- 0.02
- Profit margin
- 20.0%
- Beta
- 0.11
- Volume today
- 7,589
- Average volume
- 24,470
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| Year to December 2022 | ₹2,727.20 Cr | ₹620.60 Cr |
| Year to December 2023 | ₹1,981.60 Cr | ₹602.90 Cr |
| Year to December 2024 | ₹1,989.00 Cr | ₹413.50 Cr |
| Year to December 2025 | ₹1,823.40 Cr | ₹326.70 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹492 Cr | ₹117 Cr | +53.6% |
| Q1 FY27Apr–Jun 2026 | ₹438 Cr | ₹84 Cr | +20.1% |
| Q4 FY26Jan–Mar 2026 | ₹472 Cr | ₹103 Cr | −14.1% |
| Q3 FY26Oct–Dec 2025 | ₹420 Cr | ₹62 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹475 Cr | ₹76 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹406 Cr | ₹70 Cr | – |
Source: Sanofi India’s results filed with NSE, standalone (the company alone). Net profit is the share of Sanofi India’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | June 2026 | December 2025 |
|---|---|---|
| Fixed assets | ₹309 Cr | ₹315 Cr |
| Inventories | ₹311 Cr | ₹312 Cr |
| Owed by customers | ₹232 Cr | ₹177 Cr |
| Cash and equivalents | ₹359 Cr | ₹263 Cr |
| Total assets | ₹1,407 Cr | ₹1,255 Cr |
| Borrowings | ₹0 | ₹0 |
| Total liabilities | ₹581 Cr | ₹506 Cr |
| Shareholders’ equity | ₹826 Cr | ₹749 Cr |
Source: Sanofi India’s half-yearly statements of assets and liabilities filed with NSE, standalone. Companies file these every September and March.
About Sanofi India
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited operates as a subsidiary of Hoechst GmbH.
- Industry
- Drug Manufacturers - General
- Based in
- Mumbai
- Employees
- 1,097
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Sanofi India in the last day or two.
Dividends and corporate actions
All companies- Interim Dividend - Rs 75 Per Share
Dividend · ex-date 5 November 2026
- Dividend - Rs 48 Per Share
Dividend · ex-date 22 April 2026
- Interim Dividend - Rs 75 Per Share
Dividend · ex-date 7 November 2025
- Dividend - Rs 117 Per Share
Dividend · ex-date 25 April 2025
- Demerger
Action · ex-date 13 June 2024
- Annual General Meeting
Action · ex-date 3 May 2024
- Dividend - Rs 117 Per Share
Dividend · ex-date 3 May 2024
- Interim Dividend - Rs 50 Per Share
Dividend · ex-date 7 March 2024
Source: NSE. Latest first, 8 of 20.
Information only, not investment advice. Prices are delayed.